152 related articles for article (PubMed ID: 25846366)
1. Pronamide: Weight of evidence for potential estrogen, androgen or thyroid effects.
Marty MS; Papineni S; Coady KK; Rasoulpour RJ; Pottenger LH; Eisenbrandt DL
Regul Toxicol Pharmacol; 2015 Jul; 72(2):405-22. PubMed ID: 25846366
[TBL] [Abstract][Full Text] [Related]
2. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
4. Mode of action and human relevance of pronamide-induced rat thyroid tumors.
Papineni S; Marty MS; Rasoulpour RJ; LeBaron MJ; Pottenger LH; Eisenbrandt DL
Regul Toxicol Pharmacol; 2015 Apr; 71(3):541-51. PubMed ID: 25707858
[TBL] [Abstract][Full Text] [Related]
5. Characterization of nuclear receptor-mediated murine hepatocarcinogenesis of the herbicide pronamide and its human relevance.
LeBaron MJ; Rasoulpour RJ; Gollapudi BB; Sura R; Kan HL; Schisler MR; Pottenger LH; Papineni S; Eisenbrandt DL
Toxicol Sci; 2014 Nov; 142(1):74-92. PubMed ID: 25092647
[TBL] [Abstract][Full Text] [Related]
6. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
7. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
8. Pronamide: Human relevance of liver-mediated rat leydig cell tumors.
Rasoulpour RJ; Andrus AK; Marty MS; Zhang F; Thomas J; LeBaron MJ; Papineni S; Pottenger LH; Eisenbrandt DL
Regul Toxicol Pharmacol; 2015 Jul; 72(2):394-404. PubMed ID: 25846364
[TBL] [Abstract][Full Text] [Related]
9. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
10. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
12. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ammonium perchlorate in the endocrine disruptor screening and testing program's male pubertal protocol: ability to detect effects on thyroid endpoints.
Stoker TE; Ferrell JM; Laws SC; Cooper RL; Buckalew A
Toxicology; 2006 Nov; 228(1):58-65. PubMed ID: 17011691
[TBL] [Abstract][Full Text] [Related]
14. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
15. Relevance weighting of tier 1 endocrine screening endpoints by rank order.
Borgert CJ; Stuchal LD; Mihaich EM; Becker RA; Bentley KS; Brausch JM; Coady K; Geter DR; Gordon E; Guiney PD; Hess F; Holmes CM; LeBaron MJ; Levine S; Marty S; Mukhi S; Neal BH; Ortego LS; Saltmiras DA; Snajdr S; Staveley J; Tobia A
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):90-113. PubMed ID: 24510745
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
[TBL] [Abstract][Full Text] [Related]
17. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
18. Assessing utility of thyroid in vitro screening assays through comparisons to observed impacts in vivo.
Eytcheson SA; Olker JH; Friedman KP; Hornung MW; Degitz SJ
Regul Toxicol Pharmacol; 2023 Oct; 144():105491. PubMed ID: 37666444
[TBL] [Abstract][Full Text] [Related]
19. Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors.
Keane KA; Parker GA; Regan KS; Picut C; Dixon D; Creasy D; Giri D; Hukkanen RR
Toxicol Pathol; 2015 Dec; 43(8):1047-63. PubMed ID: 25948506
[TBL] [Abstract][Full Text] [Related]
20. Hypothesis-driven weight-of-evidence analysis of endocrine disruption potential: a case study with triclosan.
Mihaich E; Capdevielle M; Urbach-Ross D; Slezak B
Crit Rev Toxicol; 2017 Apr; 47(4):263-285. PubMed ID: 28128023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
